Apollon Formularies (AQSE:APOL) Capex-to-Revenue : 0.00 (As of Jun. 2023)

View and export this data going back to . Start your Free Trial

What is Apollon Formularies Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Apollon Formularies's Capital Expenditure for the six months ended in Jun. 2023 was £0.00 Mil. Its Revenue for the six months ended in Jun. 2023 was £0.05 Mil.

Hence, Apollon Formularies's Capex-to-Revenue for the six months ended in Jun. 2023 was 0.00.

Apollon Formularies Capex-to-Revenue Historical Data

The historical data trend for Apollon Formularies's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollon Formularies Capex-to-Revenue Chart

Apollon Formularies Annual Data

Trend

Jun10

Jun11

Dec12

Dec13

Dec14

Dec17

Dec18

Dec19

Dec20

Dec21

Capex-to-Revenue

Get a 7-Day Free Trial

Apollon Formularies Semi-Annual Data
	Jun11	Jun12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec17	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Jun23
Capex-to-Revenue	Get a 7-Day Free Trial											-	-	-	-	-

Competitive Comparison of Apollon Formularies's Capex-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Apollon Formularies's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Apollon Formularies's Capex-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Apollon Formularies's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Apollon Formularies's Capex-to-Revenue falls into.

Apollon Formularies Capex-to-Revenue Calculation

Apollon Formularies's Capex-to-Revenue for the fiscal year that ended in Dec. 2021 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (0)	/	0.198
	=	0.00

Apollon Formularies's Capex-to-Revenue for the quarter that ended in Jun. 2023 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (0)	/	0.048
	=	0.00

Apollon Formularies (AQSE:APOL) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

Apollon Formularies Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Apollon Formularies's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Apollon Formularies (AQSE:APOL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Apollon Formularies PLC (AQSE:APOL) » Definitions » Capex-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

6 Hope Street, Quayside House, Castletown, IMN, IM9 1AS

Website

https://www.apollon.org.uk

Apollon Formularies PLC is a London, England and Jamaican based medical cannabis pharmaceutical company specialising in research and treatment of patients with cancer and chronic pain. It is engaged in investing by seeking to acquire a direct and/or indirect interest in projects and assets in the agriculture and logistics sectors and the medicinal cannabis sector. The company focus on opportunities in Africa and Europe. It has created proprietary hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products.